[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336147-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336147-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-research-and-treatment-of-breast-cancer-20-editorial","Molecular Research and Treatment of Breast Cancer 2.0 - Editorial","","Breast cancer remains a leading cause of cancer-related deaths among women, driven by complex and diverse molecular mechanisms that complicate treatment selection and outcome prediction. Progress in molecular research has clarified cellular pathways supporting tumor progression, enabling new diagnostic markers and therapeutic strategies highlighted in this Special Issue. The editorial outlines molecular subtypes based on histopathology and receptor expression (ER, PR, HER2), as well as genomic and transcriptomic profiling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-research-and-treatment-of-breast-cancer-20-editorial/336147/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-research-and-treatment-of-breast-cancer-20-editorial/336147.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes breast cancer treatment selection difficult according to the editorial?","Question",{"text":63,"@type":64},"Breast cancer is shaped by intricate molecular mechanisms and substantial molecular diversity. This heterogeneity limits accurate prediction of disease outcomes and complicates choosing effective therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are breast cancer molecular subtypes distinguished?",{"text":68,"@type":64},"Subtypes are distinguished using histopathological assessment of primary tumors and expression levels of hormone receptors (ER, PR) and HER2/Neu. Additional genomic and transcriptomic profiling further refines subtype classification.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanisms are highlighted for endocrine resistance in ER-positive breast cancer?",{"text":72,"@type":64},"The editorial emphasizes resistance involving ER pathway alterations, including hormone-independent activation, gain-of-function mutations, changes in ER/coactivator-corepressor interactions, and cross-talk with growth factor receptor/oncogenic signaling. It also notes alternative splicing as another contributing mechanism.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336147,1790633985,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Editorial  \nMolecular Research and Treatment of Breast Cancer 2.0 Anna Kawiak   \nCitation: Kawiak, A. Molecular Research and Treatment of Breast Cancer 2.0 . Int. J. Mol. Sci. 2024, 25, 3932. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25073932  \nReceived: 12 March 2024  \nAccepted: 18 March 2024  \nPublished: 1 April 2024  \nCopyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nIntercollegiate Faculty of Biotechnology, University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland; [anna.kawiak@biotech.ug.edu.pl](anna.kawiak@biotech.ug.edu.pl)  \nBreast cancer is the primary contributor to cancer-related deaths among women. The intricacy of the molecular mechanisms underlying the onset and advancement of tumors contributes to the varied nature of breast cancer. This molecular diversity presents a significant obstacle in selecting treatment options and predicting disease outcomes. Progress in molecular research has led to deeper insights into the cellular pathways determining breast tumor progression. Such advancements have paved the way for recognizing novel diagnostic markers and developing innovative therapeutic approaches, a selection of which is presented in this Special Issue.  \nBreast cancer molecular subtypes are distinguished based on the histopathological assessment of primary tumors, the expression levels of hormone receptors (estrogen receptors (ERs) and progesterone receptors (PRs)), and epidermal growth factor receptor 2 (HER2/Neu), alongside additional genomic and transcriptomic profiling. These subtypes include normal breast-like, luminal A (ER+/PR+ with low Ki67), luminal B (ER+/PR+ with HER2+ or HER2 − and high Ki67), HER2-enriched (HER2+), basal-like, and claudinlow. Apart from the diversity of these molecular subtypes, patient-specific intertumoral variations, as well as intratumoral heterogeneity in the cell populations within a patient’s primary tumor and metastases, can significantly impact their treatment choices and outcomes [1] .  \nLuminal, hormone-receptor-positive breast cancers comprise around two thirds of breast cancer cases [2] . The predominant therapeutic approach to hormone-receptive breast cancers is targeting their ERs or suppressing estrogen production. Endocrine therapies include selective estrogen receptor mediators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs) . Despite the clinical advantages of endocrine therapy, around 20% of patients develop de novo or acquired resistance, which poses a significant clinical hurdle for individuals with hormone-responsive breast cancer. The mechanisms underlying endocrine resistance are complex, with a loss of ER expression occurring in only around 10% of endocrine-resistant breast tumors. More frequently, endocrine resistance is driven by the hormone-independent activation of ERs, which either involves gain-of-function mutations in the ER, changes in ER and coactivator/corepressor interactions, or the compensatory cross-talk between ERs and growth factor receptor/oncogenic signaling pathways [3] . Endocrine resistance can also occur due to alternative splicing, which contributes to the formation of alternative splice variants. In the case of tamoxifen, a SERM used in the first-line treatment of ER+ breast cancer, a novel variant BQ323636.1 (BQ) of the nuclear receptor corepressor 2 (NCOR2) has been shown to mediate tamoxifen resistance [4] . Research has shown that tamoxifen participates in increasing BQ’s expression through the induction of DNA damage and the activation of ATM/CHK2 signaling. CHK2 induces the phosphorylation of BQ, increasing its stability. In vivo analysis showe","cbCainx7nRXfup2R","https://ap.wps.com/l/cbCainx7nRXfup2R","pdf",191862,"English","# Editorial\n## Molecular diversity and treatment challenges\n## Breast cancer molecular subtypes and profiling\n## Endocrine therapy and mechanisms of resistance\n## Targeting CHK2 and BQ-mediated tamoxifen resistance\n## Cross-resistance of SERMs/SERDs and AIs\n## Epigenetic mechanisms and m6A RNA modification","[{\"question\":\"What makes breast cancer treatment selection difficult according to the editorial?\",\"answer\":\"Breast cancer is shaped by intricate molecular mechanisms and substantial molecular diversity. This heterogeneity limits accurate prediction of disease outcomes and complicates choosing effective therapies.\"},{\"question\":\"How are breast cancer molecular subtypes distinguished?\",\"answer\":\"Subtypes are distinguished using histopathological assessment of primary tumors and expression levels of hormone receptors (ER, PR) and HER2/Neu. Additional genomic and transcriptomic profiling further refines subtype classification.\"},{\"question\":\"What mechanisms are highlighted for endocrine resistance in ER-positive breast cancer?\",\"answer\":\"The editorial emphasizes resistance involving ER pathway alterations, including hormone-independent activation, gain-of-function mutations, changes in ER/coactivator-corepressor interactions, and cross-talk with growth factor receptor/oncogenic signaling. It also notes alternative splicing as another contributing mechanism.\"}]","Molecular Research and Treatment of Breast Cancer 2.0 - Editorial | PDF",1790013813,13,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5ac0210452aa399d3101a230cf86182.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ce3ea8dc914f9a5b60bc6f599031cbd.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2ccf2583d4a4378515a9fac44c01400.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/887eb409d993ba57447d81a9f0eac0f9.webp",980,1385]